The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
Official Title: Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study
Study ID: NCT01232881
Brief Summary: This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.
Detailed Description: OUTLINE: This is a multi-center study. Sample Collection: * Tumor sample * Serum sample Treatment Regimen: * All registered patients must be planning treatment with lonafarnib
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Name: George Sledge, M.D.
Affiliation: Hoosier Cancer Research Network
Role: STUDY_CHAIR